{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:13:42Z","timestamp":1780582422610,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,11,28]],"date-time":"2015-11-28T00:00:00Z","timestamp":1448668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00228-015-1988-7","type":"journal-article","created":{"date-parts":[[2015,11,27]],"date-time":"2015-11-27T23:41:41Z","timestamp":1448667701000},"page":"295-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Effect of commercial Rhodiola rosea on CYP enzyme activity in humans"],"prefix":"10.1007","volume":"72","author":[{"given":"Ole Kristian","family":"Thu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Spigset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odd Georg","family":"Nilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent","family":"Hellum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,28]]},"reference":[{"issue":"7","key":"1988_CR1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.phymed.2010.02.002","volume":"17","author":"A Panossian","year":"2010","unstructured":"Panossian A, Wikman G, Sarris J (2010) Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine 17(7):481\u2013493. doi: 10.1016\/j.phymed.2010.02.002","journal-title":"Phytomedicine"},{"issue":"11","key":"1988_CR2","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1055\/s-0029-1185720","volume":"75","author":"J Blomkvist","year":"2009","unstructured":"Blomkvist J, Taube A, Larhammar D (2009) Perspective on roseroot (Rhodiola rosea) studies. Planta Med 75(11):1187\u20131190. doi: 10.1055\/s-0029-1185720","journal-title":"Planta Med"},{"issue":"4","key":"1988_CR3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0029-1186153","volume":"76","author":"BH Hellum","year":"2010","unstructured":"Hellum BH, Tosse A, Hoybakk K, Thomsen M, Rohloff J, Georg Nilsen OG (2010) Potent in vitro inhibition of CYP3A4 and P-glycoprotein by Rhodiola rosea. Planta Med 76(4):331\u2013338. doi: 10.1055\/s-0029-1186153","journal-title":"Planta Med"},{"issue":"3","key":"1988_CR4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ptr.2631","volume":"23","author":"A Panossian","year":"2009","unstructured":"Panossian A, Hovhannisyan A, Abrahamyan H, Gabrielyan E, Wikman G (2009) Pharmacokinetic and pharmacodynamic study of interaction of Rhodiola rosea SHR-5 extract with warfarin and theophylline in rats. Phytother Res 23(3):351\u2013357. doi: 10.1002\/ptr.2631","journal-title":"Phytother Res"},{"issue":"1\u20132","key":"1988_CR5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000345929","volume":"91","author":"M Spanakis","year":"2013","unstructured":"Spanakis M, Vizirianakis IS, Batzias G, Niopas I (2013) Pharmacokinetic interaction between losartan and Rhodiola rosea in rabbits. Pharmacology 91(1\u20132):112\u2013116. doi: 10.1159\/000345929","journal-title":"Pharmacology"},{"issue":"5","key":"1988_CR6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/sj.clpt.6100187","volume":"82","author":"JY Ryu","year":"2007","unstructured":"Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, Shin JG (2007) Development of the \u201cInje cocktail\u201d for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther 82(5):531\u2013540. doi: 10.1038\/sj.clpt.6100187","journal-title":"Clin Pharmacol Ther"},{"key":"1988_CR7","unstructured":"US Food and Drug Administration (2001) Guidance for industry: bioanalytrical method validation. http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/ucm070107.pdf . Accessed March 2013"},{"issue":"6","key":"1988_CR8","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/sj.bjp.0703150","volume":"129","author":"A Soldner","year":"2000","unstructured":"Soldner A, Benet LZ, Mutschler E, Christians U (2000) Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol 129(6):1235\u20131243. doi: 10.1038\/sj.bjp.0703150","journal-title":"Br J Pharmacol"},{"issue":"11","key":"1988_CR9","first-page":"882","volume":"68","author":"JS Choi","year":"2013","unstructured":"Choi JS, Choi JS, Choi DH (2013) Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. Pharmazie 68(11):882\u2013888","journal-title":"Pharmazie"},{"issue":"6","key":"1988_CR10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0009-9236(95)90020-9","volume":"58","author":"MW Lo","year":"1995","unstructured":"Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58(6):641\u2013649. doi: 10.1016\/0009-9236(95)90020-9","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1988_CR11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2002.121216","volume":"71","author":"U Yasar","year":"2002","unstructured":"Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F, Eliasson E, Dahl ML (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71(1):89\u201398. doi: 10.1067\/mcp.2002.121216","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1988_CR12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s002280050405","volume":"53","author":"KM Kaukonen","year":"1998","unstructured":"Kaukonen KM, Olkkola KT, Neuvonen PJ (1998) Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 53(6):445\u2013449","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1988_CR13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11239-007-0164-z","volume":"26","author":"A Ahmed","year":"2008","unstructured":"Ahmed A, Stephens JC, Kaus CA, Fay WP (2008) Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin. J Thromb Thrombolysis 26(1):44\u201348. doi: 10.1007\/s11239-007-0164-z","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"1988_CR14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/0091270003261333","volume":"44","author":"H Zhou","year":"2004","unstructured":"Zhou H, Tong Z, McLeod JF (2004) \u201cCocktail\u201d approaches and strategies in drug development: valuable tool or flawed science? J Clin Pharmacol 44(2):120\u2013134. doi: 10.1177\/0091270003261333","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1988_CR15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1248\/bpb.b13-00401","volume":"37","author":"S Tanaka","year":"2014","unstructured":"Tanaka S, Uchida S, Inui N, Takeuchi K, Watanabe H, Namiki N (2014) Simultaneous LC-MS\/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 substrate drugs and their metabolites. Biol Pharm Bull 37(1):18\u201325","journal-title":"Biol Pharm Bull"},{"key":"1988_CR16","author":"G An","year":"2015","unstructured":"An G, Mukker JK, Derendorf H, Frye RF (2015) Enzyme- and transporter-mediated beverage-drug interactions: an update on fruit juices and green tea. J Clin Pharmacol. doi: 10.1002\/jcph.563","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1988_CR17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jada.2004.10.027","volume":"105","author":"CD Frary","year":"2005","unstructured":"Frary CD, Johnson RK, Wang MQ (2005) Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc 105(1):110\u2013113. doi: 10.1016\/j.jada.2004.10.027","journal-title":"J Am Diet Assoc"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1988-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-015-1988-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1988-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:49:15Z","timestamp":1558702155000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-015-1988-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,28]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["1988"],"URL":"https:\/\/doi.org\/10.1007\/s00228-015-1988-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,28]]}}}